Health Professional Radio - Podcast 454422

Jim Joyce, co-founder, chairman, and CEO of Sigyn Therapeutics discusses the development of Sigyn Therapy, the company's blood purification technology to overcome the limitations of drugs and other devices to treat Cytokine Storm induced inflammatory conditions that lead to sepsis. He explains the relationship between Cytokine Storm and COVID and how this blood purification technology is an approach that is getting alot of attention right now. He talks about how this technology differs from current blood purification technologies and what the current treatment landscape looks like. #SigynTherapeutics #BloodPurificationTechnology #CytokineStorm James “Jim” Joyce has 30+ years of diverse public market experience, which includes two decades of public company CEO and Corporate Board leadership roles. He is also an inventor or co-inventor underlying 18 pending or issued patents. Prior to establishing Sigyn Therapeutics, Mr. Joyce was the founder and former Chairman and CEO of Aethlon Medical, a therapeutic technology company that he navigated from single shareholder start-up to Nasdaq-traded Company with 8000+ shareholders. During his tenure at Aethlon, Mr. Joyce oversaw the development of the Hemopurifier®, a first-in-class blood purification technology to address life-threatening viruses and cancer-promoting exosomes. Under his leadership, the Hemopurifier® became the first therapeutic candidate to be awarded two FDA “Breakthrough Device” designations and was the first and only device to receive “Emergency Use Authorization” (EAU) approval from both the FDA and Health Canada to treat Ebola virus. Time Magazine named the Hemopurifier® one of the “11 Most Remarkable Advances in Healthcare” and designated the device to its “Top 25 Best Inventions” award list. The Hemopurifier® has since been cleared by the FDA to treat severe COVID-19 infections in a clinical setting. Under Mr. Joyce's leadership, the Hemopurifier® was the subject of two Department of Defense (DOD) contract awards and a National Cancer Institute (NCI) contract. Mr. Joyce led the completion of approximately $100 million of equity financings on behalf of Aethlon Medical and established preclinical and clinical collaborations with more than twenty government and non-government research institutes. Based on the use of the Hemopurifier® to treat HIV and Hepatitis-C infected individuals in India, Mr. Joyce was the recipient of the “Spirit of India Award” sponsored by the Bill & Melinda Gates Foundation and awarded each year by the American India Foundation to the American business leader who has demonstrated a commitment to accelerate social and economic change in India. Mr. Joyce testified before Congress and lobbied Capitol Hill to promote the Hemopurifier® as a broad-spectrum countermeasure against bioterror and pandemic threats, which contributed to expanding the government-wide definition of treatment countermeasure to be inclusive of medical devices under U.S. law.

Sara Thomas, PhD, RD, registered dietician and research scientist at Abbott, discusses a new study from Abbott and The Ohio State University that was published in "Nutrients" that showed that adults with diabetes with low protein leads to physical limitations, lower overall diet quality, poorer nutrition density and more carbohydrates consumed. #Abbott #Nutrients Sara Thomas , PhD, RD is a registered dietitian and a research scientist supporting the Global Science team at Abbott. Sara provides clinical and scientific expertise for Abbott's adult nutrition products and specializes in diabetes and oncology. Previously, Sara has worked in various roles in the field of nutrition including academic, government, and industry settings. Her previous nutrition research experience includes carotenoids, adult obesity, and dietary supplements. Sara earned her master's degree and PhD in Nutrition Science and completed her dietetic internship at the Ohio State University and conducted her post-doctoral training at the USDA. Areas of Expertise: Adult nutrition, diabetes and prediabetes, and oncology

Rami Levin, President and CEO of Saniona discusses Tesomet, the first and only investigational treatment for Hypothalamic Obesity (HO) to receive orphan drug designation. This marks a major milestone for the patient community as there are currently no medications specifically approved for HO. Patients living with this disease experience uncontrollable hunger and intractable weight gain, which is often complicated by depression, impulse control issues and increased risk of cardiovascular and metabolic disorders. This milestone builds on the orphan drug designation granted by the FDA earlier this year to Tesomet for the treatment of Prader-Willi Syndrome (PWS) and Saniona is preparing to initiate Phase 2b studies of Tesomet in HO and PWS in the second half of this year.​ #Saniona #HypothalamicObesity Rami Levin, President and Chief Executive Officer. Rami Levin (born 1969) is a seasoned biotech leader with over 24 years of experience in rare diseases and central nervous system disorders. Prior to joining Saniona in January 2020, he most recently served as President of Sobi Inc., the North American affiliate of international rare disease company Sobi. At Sobi, he built and led the North American organization from infancy to a team of approximately 300 employees generating over half a billion USD in annual revenue. Levin's experience in mergers and acquisitions resulted in the successful acquisitions of Gamifant, the first FDA approved treatment for primary hemophagocytic lymphohistiocytosis (pHLH), and Synagis, the only FDA approved prophylaxis for respiratory syncytial virus (RSV). Under his leadership, the Sobi team launched Gamifant and integrated the entire Synagis sales and medical organizations, retaining 100% of the team. Prior to joining Sobi, Levin held commercial leadership roles of increasing strategic importance for 16 years at Merck Serono in a number of countries, including the U.S., Sweden, Switzerland and Israel. Levin earned his MBA from the Recanati Business School at Tel Aviv University in Israel, majoring in International Marketing, and has a BSc in Biology from Tel Aviv University. In addition to his current position as President and CEO of Saniona, Levin serves as a member of the Board of Advisors for Life Science Cares. Levin holds 10,000 shares and 710,313 options in the options program 2020/2024 and 1,262,000 options in the options program 2020/2031.

Dr. Bruce Bender, PhD, lead researcher and co-director of the Center for Health Promotion at National Jewish Health discusses recent research published in "The Journal of Allergy and Clinical Immunology: In Practice" about The Asthma Toolkit Bootcamp, a program that improved physician adherence to current guidelines, leading to fewer hospitalizations, emergency room visits, and decreased use of oral medications. #AsthmaToolkitBootcamp Dr. Bender is a member of the faculty at National Jewish Health, where he initiated the pediatric neuropsychology service. From this service, he began a research program designed to examine incidence and correlates of cognitive impairment in children with asthma, leading to a series of studies on the neuropsychological side effects of medications used to treat allergies and asthma. He has an ongoing research program that investigates health care behaviors that moderate asthma treatment effects, and the psychological disorders that undermine adherence. Dr. Bender is the head of the Division of Pediatric Behavioral Health, a team of seven psychologists, social workers, art therapists, and psychiatrists who provide services to children with chronic illness and their families. In 2006, he helped to establish the Colorado Asthma Tool Kit Program to address medically underserved asthma patients around the state, including those with low incomes, who speak Spanish as a first language or who live in rural locations. This program teaches health care providers to deliver care that is consistent with the most current evidence-based guidelines and, importantly, how to provide effective self-management education to adults, children and parents. The Asthma Toolkit program has since become the Respiratory Toolkit program, providing primary care training in both asthma and chronic obstructive pulmonary disease. Dr. Bender is a fellow of the American Academy of Allergy, Asthma and Immunology, and the recipient of a lifetime achievement award from the American Thoracic Society.

Daniel Shapiro, author of "The Thin Ledge: A Husband's Memoir of Love, Trauma, and Unexpected Circumstances" shares the reality of the fifteen years he spent living and caring for his wife, who suffered two massive brain hemorrhages and a personality change, while also single handedly raising their three young children. He discusses moving on and growing from trauma, moral issues, the struggle of a caregiver, and his perspective as a male caregiver. This book addresses questions that people living through unspeakable misfortunes may never mention, but almost always ask. ​​ #PersonalGrowth #HealingAfterTrauma Dan Shapiro is a member of the Board of Trustees of the Brain Research Foundation, a foundation that exists to accelerate discoveries of the human brain by funding pioneering neuroscience research. Dan's three children co-founded the Young Leadership Board in 2016 and have raised more than $260,000 for BRF. Dan is a graduate of the University of Chicago Law School. A lifelong Chicagoan, he has practiced trial law nationally for many years. He enjoys spending his time reading and hanging out with his grown children The Thin Ledge is his debut book. He is currently at work on a second book, a novel about an aging lawyer, late career ambition, and ethnicity in a changing, woke world.

Adam Sachs, co-founder and CEO of Vicarious Surgical, a company backed by Bill Gates and Vinod Khosla, discusses the company's Fantastic Voyage inspired-surgical robot that uses immersive reality to guide today's surgeons inside the body with new, groundbreaking technology that sets it apart from competitors. The system has received FDA Breakthrough Device designation. #VicariousSurgical #SurgicalRoboticsDisrupter Adam Sachs is CEO of Vicarious Surgical, a surgical robotics company he co-founded in 2014. Sachs leads the development and commercialization of the company's surgical robots to increase the efficiency of procedures and improve patient outcomes. Prior to founding Vicarious Surgical, Sachs worked at Apple in manufacturing. He holds a Bachelor of Science in mechanical engineering from MIT and has worked for more than 11 years as a volunteer emergency medical technician for MIT EMS, an ambulance serving the MIT community.

Hideki Garren, MD, PhD, Chief Medical Officer at Prothena discusses data from two presentations at the Alzheimer's Association International Conference (AAIC); PRX012, Prothena's next generation anti-amyloid beta (Aβ) antibody and the dual Aβ-tau vaccine being developed for the prevention and treatment of Alzheimer's Disease (AD). He talks about the company's approach to addressing the AD global healthcare crisis. #Alzheimer #AAIC H​ideki Garren, M.D., Ph.D.​, Chief Medical Officer​. Dr. Garren has served as our Chief Medical Officer since April 2021. Before joining Prothena, between 2013 and 2021 Dr. Garren was with F. Hoffmann-La Roche Ltd. (Roche) & Genentech Inc. and most recently served as Vice President, Global Head of Neuroimmunology with responsibility for leading Roche's Neuroimmunology franchise team. Prior to Roche, between 2011 and 2013, Dr. Garren held the role of Executive Director, Translational Medicine Expert in Neuroscience with Novartis Pharma. Dr. Garren also served as Co-Founder, Executive Vice President, Chief Scientific Officer, and Chief Operating Officer of Bayhill Therapeutics, Inc., a company he started in 2002 based on a technology platform he co-invented while at Stanford University. He currently serves on the board of directors of Coya Therapeutics, a privately-held clinical-stage biotechnology company. Dr. Garren earned his Bachelor of Science from the California Institute of Technology and his MD and PhD from the University of California, Los Angeles (UCLA). He completed his internship in internal medicine at UCLA, and his residency in neurology and fellowship in neuroimmunology at Stanford University.

Dr. Cindy Jacobs, PhD, MD, President and Chief Medical Officer at Achieve Life Sciences discusses the grant that was awarded from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) to evaluate the use of cytisinicline as a treatment for the cessation of nicotine e-cigarette use. #AchieveLifeSciences Cindy Jacobs, Ph.D., M.D. · President & Chief Medical Officer, Achieve Life Sciences Inc. Dr. Jacobs is an experienced executive in drug development with expertise in several indications and over 30 years' experience in Biotechnology/Pharmaceutical industry. Dr Jacobs has achieved regulatory success in several product approvals. Prior to joining Achieve Life Sciences in 2017, Dr. Jacobs served as OncoGenex's Executive Vice President and Chief Medical Officer since August 2008, and had been Executive Vice President and Chief Medical Officer of OncoGenex Technologies Inc. from September 2005 to August 2008. From 1999 to July 2005, Dr. Jacobs served as Chief Medical Officer and Senior Vice President, Clinical Development of Corixa Corporation. Prior to 1999, Dr. Jacobs held Vice President, Clinical Research positions at two other biopharmaceutical companies. Dr. Jacobs received her Bachelor's degree in Microbiology from Montana State University, her Master's degree and Ph.D. degree in Veterinary Pathology/Microbiology from Washington State University and an M.D. degree from the University of Washington Medical School. She has in-depth biotechnology experience in preclinical development, pharmacokinetic/drug metabolism studies, toxicology studies, clinical operations, Phase 1-4 trials in a variety of therapeutic areas, regulatory affairs, biostatistics, data management, medical information and quality assurance. Based on her preclinical work at Immunex Corporation, she is one of 2 inventors on the patent for Enbrel.

Returning guest, Cathy Kuhn, PharmD, Director, Voice of the Customer at Updox, a complete healthcare communication platform for in-person and virtual care, discusses their recently released "Paperless Practice Playbook" with tips for providers on how to increase productivity, improve patient engagement and reduce burnout. She talks about why providers must eliminate paper in order to reduce the amount of time spent on administrative tasks for both provider and patients and how one practice saved more than 500 hours a year on administrative tasks by leveraging a paperless practice. #Productivity #PatientEngagement #ReduceBurnout Cathy Kuhn, PharmD, BCACP, FAPhA, is the Director of Strategy Consulting at Updox. She is past president of the Ohio Pharmacists Association and current president of the American Pharmacist's Association's (APhA) Academy of Pharmacy Practice and Management and APhA board member. Cathy's service to the profession has given her a front-row seat to a pharmacists' positive impact, and fuels her drive to claim a pharmacist's role as members of the healthcare team and to operate at the top of the licensure.

Derek Wallace, Vice President and Dengue Global Program Lead at Takeda, discusses the first public presentation of long-term safety and efficacy results from the ongoing pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial of its dengue vaccine candidate, TAK-003, and the launch of the company's global HCP dengue education platform, Dengue Academy. #Dengue #DengueVaccine Derek Wallace, MBBS, is Vice President and Global Dengue Program Head at Takeda. In this role, Mr. Wallace leads the global program team in the development of Takeda's dengue vaccine candidate (TAK-003). Mr. Wallace joined Takeda in September 2013 as Global Programme Medical Director responsible for the development of TAK-003 as well as Takeda's enterovirus vaccine candidate.Mr. Wallace has over 16 years of experience in clinical development, infectious diseases and medical affairs. Prior to joining Takeda, Mr. Wallace held clinical development and medical affairs positions at Merck, Novartis and Sanofi Pasteur. At Sanofi, Mr. Wallace served as clinical team leader for Sanofi's dengue vaccine candidate, influenza studies and preparations for first-in-human studies of vaccine candidates for malaria and meningitis B. His experience also includes transplant, cardiology and women's health.Mr. Wallace holds a Diploma of Vaccinology from the Institut Pasteur and a Diploma in Pharmaceutical Medicine from University of Wales, Cardiff. He received his Bachelor of Medicine, Bachelor of Surgery from the University of Queensland.

Mike Rea, is founder of Protodigm, a contract skunkworks lab specializing in minimizing the risk of drug development by avoiding bias, premature specialization, and providing clients a universe of possibilities in which a drug could be brought to market. He talks about how the use of the skunkworks concept common in tech and engineering can innovate drug development. #Protodigm #DrugDevelopment Mike is the founder of Protodigm, a next generation CRO that innovates, invents, develops, and prototypes possibilities for drugs to be brought to market, as well as the CEO and founder of IDEA Pharma, a specialist in pharmaceutical product positioning and path-to-market strategies. He has delivered positioning and strategy for eight of the fifteen biggest drug launches in the last five years. After having been named to The Medicine Maker's Global Power List 100 from 2017 to 2019, in 2020 and 2021 he was added to the Global Power List 20: the top 20 inspirational medicine makers in biopharmaceuticals. PharmaPhorum has named him as one of the Top 10 Innovators in Pharma and PharmaVOICE awarded him with a lifetime Red Jacket as one of the 100 Most Inspiring People in Healthcare. He is the author of the Medical Marketing Manual: Branding Pharmaceuticals and the Pharmaceutical Innovation Index. Mike earned his bachelor's degree in genetics from the University of Newcastle-upon-Tyne.

As the most common type of non-cancerous tumors in women of reproductive age, uterine fibroids can cause physical symptoms, including heavy menstrual bleeding. Additionally, uterine fibroids can take a significant toll on quality of life, relationships and intimacy, employment, and create an overall reduced quality of well-being in a patient's health. Dr. Veronica Gillispie-Bell, Senior Site Lead and Section Head of Obstetrics and Gynecology at Ochsner Kenner in New Orleans discusses heavy menstrual bleeding as a symptom of uterine fibroids, options in the treatment landscape, including ORIAHNN™, the first, non-surgical, oral medication developed specifically to treat heavy menstrual bleeding associated with uterine fibroids in premenopausal patients. She also shares how HCPs can open a dialogue with patients about their individual symptoms, lifestyle and treatment goals, and to address their concerns sooner rather than later. #UterineFibroids #ORIAHNN Veronica Gillispie-Bell, MD, MS, is a practicing ob-gyn and section head of women's services at Ochsner Kenner in New Orleans. She is the Medical Director of the Louisiana Perinatal Quality Collaborative (LaPQC) and Pregnancy Associated Mortality Review with the LA Department of Health. She is an associate professor and director of the Center for Minimally Invasive Treatment of Uterine Fibroids. Dr. Veronica Gillispie-Bell is a Board-Certified Obstetrician & Gynecologist and Associate Professor for Ochsner Health in New Orleans, Louisiana. She serves as the Senior Site Lead and Section Head of Obstetrics and Gynecology at Ochsner Kenner. Additionally, she serves as the Director of Quality for Women's Services for the Ochsner Health System and is an associate professor and director of the Center for Minimally Invasive Treatment of Uterine Fibroids. Dr. Gillispie-Bell is also the Medical Director of the Louisiana Perinatal Quality Collaborative and Pregnancy Associated Mortality Review for the Louisiana Department of Health. She earned her medical degree from Meharry Medical College and completed her residency training at Ochsner Health System. She also earned a Master of Applied Science in Patient Safety and Healthcare Quality from the Johns Hopkins Bloomberg School of Public Health. Additionally, she has received certification in Diversity and Inclusion from Cornell University

Dr. ​Steve Roman​o​, ​MD, ​Executive Vice President and Chief Scientific Officer at Mallinckrodt Pharmaceuticals discusses the results of their pivotal Phase 3 STRATA2016 clinical trial of StrataGraft ®, an investigational allogeneic cellularized scaffold product in development for the treatment of adult patients with deep partial-thickness burns. The data was published in "Burns" peer review journal (July 2021). It received FDA approval in July 2021 and can provide burn surgeons with an alternative biologic treatment option for patients with deep partial-thickness burns. #MallinckrodtPharmaceuticals #STRATA2016 Dr. Steven Romano is executive vice president and chief scientific officer at Mallinckrodt Pharmaceuticals. He has executive responsibility for research and development (R&D), medical affairs and regulatory affairs functions, and is a member of Mallinckrodt's executive committee. A board-certified psychiatrist, Dr. Romano has more than 20 years of experience in the pharmaceutical industry. Prior to joining Mallinckrodt, he spent 16 years at Pfizer, Inc. where he held a series of senior medical and R&D roles of increasing responsibility, culminating in his most recent position as SVP, Head, Global Medicines Development, Global Innovative Pharmaceuticals Business. Prior to joining Pfizer, he spent four years at Eli Lilly. After receiving an A.B. in biology from Washington University and a medical degree from the University of Missouri-Columbia, Dr. Romano completed his residency and fellowship at New York Hospital-Cornell Medical Center, continuing on the faculty of the medical school for six additional years.

Nearly 1.8 million people globally die of lung cancer each year, more than the second and third most deadly cancers combined (colorectal and stomach cancer, respectively) because it is often detected and treated too late. Dr. Avrum "Avi" Spira, MD, MSc, Global Head of the Lung Cancer Initiative (LCI) at Johnson & Johnson, a renowned pulmonologist and lung cancer researcher, wants to make lung cancer a disease of the past. He discusses why early detection with lung cancer is key, what recent advancements in imaging, robotics and artificial intelligence have unlocked in new ways to screen for and access cancer, and how LCI is working to develop solutions to prevent, intercept and cure lung cancer. #LungCancer #LungCancerInitiative Avrum “Avi” Spira, MD, MSC, is the Global Head of the Lung Cancer Initiative (LCI) at Johnson & Johnson, which is developing solutions to prevent, intercept and cure lung cancer. Practicing medicine for more than 20 years, Dr. Spira leads a team of dedicated industry leaders and medical professionals focused on developing novel technologies and approaches that support earlier lung cancer detection and treatment. In addition to leading the Lung Cancer Initiative at Johnson & Johnson, Dr. Spira is an attending physician in the Medical Intensive Care Unit at Boston University-Boston Medical Center (BMC) and is a Professor of Medicine, Bioinformatics and Pathology at Boston University. He also serves as the Alexander Graham Bell Professor in Health Care Entrepreneurship at Boston University. Prior to joining Johnson & Johnson, he was the Director of the Boston University-BMC Cancer Center, and was the founding Chief of the Division of Computational Biomedicine at Boston University.

Dr. Chris Anzalone, PhD, President and CEO of Arrowhead Pharmaceuticals discusses new positive patient-level data from their AROAAT2002 global Phase 2 study of ARO-AAT, an RNA therapeutic being co-developed by the company and Takeda, in patients with liver disease caused by alpha-1 antitrypsin deficiency (AATD). He also talks about the company's RNAi platform. #ArrowheadPharmaceuticals #LiverDisease Dr. Christopher Anzalone has been President, Chief Executive Officer and Director of the Company since December 1, 2007. In 2005, Dr. Anzalone formed and served as CEO of the Benet Group LLC, a private equity firm focused on creating and building new nano-biotechnology companies from university-generated science. Prior to his tenure at the Benet Group, he was a partner at the Washington, DC-based private equity firm Galway Partners, LLC, where he was responsible for sourcing, structuring, and building new business ventures. Prior to Galway, Dr. Anzalone was an NIH-supported post doctoral fellow in Reproductive Endocrinology at the Smithsonian Institution's Conservation and Research Center. Dr. Anzalone holds a Ph.D. in Biology from UCLA and a B.A. in Government from Lawrence University.

Dr. Arezou Khosroshahi​, ​MD, Associate Professor of Medicine at Emory University​ discusses the enrollment of the first patient in Horizon Therapeutics' Phase 2 trial to evaluate HZN-7734, ​a first- in-class, fully human monoclonal antibody to treat people with moderate to severely active systemic lupus erythematosus (SLE). SLE is an autoimmune disease where the immune system mistakenly attacks healthy cells and tissues. Of the 5 million people living with a form of lupus, SLE accounts for nearly 70 percent of cases and presents a tremendous unmet treatment need.​ #HorizonTherapeutics #SystemicLupusErythematosus Arezou Khosroshahi is an Associate Professor of Medicine in the division of Rheumatology. She joined Emory in 2012 and founded the IgG4-RD clinic at Emory. This clinic is one of the few in the United States to evaluate and treat patients with IgG4-RD with referral from all around the Southeast. She has been one of the initial investigators interested in understanding IgG4-RD since her fellowship at MGH and has played an important role in naming the disease, developing pathology statement and more recently the classification criteria for the diagnosis of IgG4-RD. She is the co-director of Emory Lupus clinic and has served at Grady Lupus clinic in the past 9 years, taking care of lupus patients in Georgia and working closely with scientists in Emory Lowance Immunology Center in understanding many different aspects of lupus in the diverse population in Atlanta with particular interest in treatment. She also currently serves as the director of clinical trials at the division of rheumatology at Emory university and has been principal investigator on multiple clinical trials in Lupus and IgG4-RD. Dr. Khosroshahi received her medical degree from Tehran University Medical School in Iran. After finishing a postdoctoral research fellowship in the Transplantation Center at the Brigham and Women's Hospital, Harvard Medical School, she completed her internal medicine training at St. Lukes-Roosevelt Hospital Center, Columbia University. She pursued her clinical rheumatology fellowship at Massachusetts General Hospital, where she became involved in clinical research and clinical trial design. Dr. Khosroshahi has a particular interest in clinical education and works closely with Emory medical students, residents, and fellows at Grady Memorial Hospital and Emory University.

Dr. James Tursi, MD, Chief Scientific Officer of Ferring Pharmaceuticals discusses developments in microbiome-based therapeutics for the treatment of recurrent C. difficile (rCDI) infection. The current standard of care treatment for rCDI is currently antibiotics. While they are important, they do not restore the underlying health of the gut microbiome, nor can they stop C. diff​icile​ spores from growing back. He talks about what their late stage pivotal Phase 3 clinical trial results showed regarding mitigating recurrent C. difficile infection.​ ​The ​gut ​microbiome is an emerging area where biotherapeutics are being developed to address certain diseases and conditions.​ #FerringPharmaceuticals #ClostridioidesDifficileInfection Dr. James Tursi is responsible for U.S. Clinical Development, Pharmaceutical Development, Medical Affairs, Pharmacovigilance (PV), Project Planning and Regulatory Affairs. James collectively has over 30 years of experience in medicine and nearly 20 years in the pharmaceutical industry. Prior to joining Ferring, as Executive Vice President, R&D, Chief Medical Officer for Antares Pharmaceuticals, he created patent extension and portfolio opportunities, was the medical-clinical-PV lead for commercial and business development activities and designed the medical/clinical commercial strategies. Before joining Antares, James held positions of increasing responsibility at Aralez Pharmaceuticals, Auxilium Pharmaceuticals, GlaxoSmithKline, and Procter & Gamble Pharmaceuticals. His therapeutic expertise includes reproductive health, urology, endocrinology (including pediatric), gastroenterology, cardiology, vascular surgery, oncology and neurology. He practiced medicine and surgery for over 10 years and created a medical education company, I Will Pass ®, which assisted physicians in the process of board certification. James holds a Bachelor of Science degree in Chemistry and Biology from Ursinus College; a Doctor of Medicine from Medical College of Pennsylvania and performed his residency in Gynecology and Obstetrics at the Johns Hopkins Hospital.

Returning guest, Dr. Kaveh Safavi, Global Health Lead of Accenture Health, discusses the findings from their 2021 Digital Health Tech Vision report that surveyed 399 healthcare executives across six countries to better understand their view of the impact technology is having on the healthcare industry and what this means for the future. #AccentureHealth #DigitalHealthTechnology Kaveh Safavi, M.D., J.D., is a senior managing director at Accenture where he is responsible for leading, developing, and driving a growth strategy that differentiates Accenture's offerings for providers, health insurers, and public and private health systems across the globe. A seasoned executive, Dr. Safavi brings more than three decades of leadership experience to Accenture Health. Prior to joining Accenture in 2011, Dr. Safavi led Cisco's global healthcare practice. Before that, he was chief medical officer of Thomson Reuters' health business, vice president of medical affairs at United Healthcare, and had leadership roles at HealthSpring and Humana. Among his many accomplishments was establishing one of the Midwest's first electronic-health-record-enabled primary care practices. Dr. Safavi has published numerous papers and is often quoted on healthcare issues in various media publications, including The Wall Street Journal, the BBC, The New York Times, Consumer Reports, US News and World Report, Harvard Business Review and The Economist. Recently, IT Services Report named him the #1 healthcare IT executive for 2020. Dr. Safavi earned an M.D. from Loyola University School of Medicine and a J.D. from DePaul University College of Law. He is board-certified in internal medicine and pediatrics and completed his medical residency at the University of Michigan Medical Center. He serves on the Weinberg College of Arts and Sciences' Board of Visitors–Northwestern University, is a frequent guest scholar at the Stanford University Clinical Excellence Research Center, and serves on the advisory committee of the Buck Institute for Research on Aging. Dr. Safavi is a lifelong Chicagoan.

Girish Navani, CEO and Cofounder of eClinicalWorks, a leader in healthcare IT solutions discusses PRISMA, the healthcare industry's first health information search engine that leverages a "one patient, one record" approach for fast and accurate decision-making that can be lifesaving. This platform helps to better know patients and provide more effective clinical care and can even cut patient wait times from approximately 30 minutes to 10 minutes. #eClinicalWorks #PRISMA Girish Navani helps set the company's vision, leading efforts to grow and expand all aspects of the business, and actively manages its Research & Development pursuits. His efforts assist in securing eClinicalWorks as both a pioneer and leader in the healthcare IT industry. He was named to Boston Business Journal's 2014 Power50 list of most influential people in Boston, honored as a 2010 Mass High Tech All-Stars honoree and received the Ernst & Young Entrepreneur Of The Year® 2009 Award in the Healthcare Technology category in New England. Navani also was chosen for the Boston Business Journal's 2006 40 Under 40 list of entrepreneurs and innovators. Prior to cofounding eClinicalWorks, Navani led successful IT and business initiatives at Fidelity Investments, Aspen Technology and Teradyne. He holds a Master of Science in Manufacturing Engineering from Boston University.

Returning guest, Dr. Larry Edwards, ​MD, MACP, MACR, rheumatologist and Chairman of the Gout Education Society discusses managing gout during the summer, with travel and get togethers, and how HCPs can prepare their patients to manage proper medications and lifestyle habits during this time. #GoutEducationSociety #ManagingGout #Gout Dr. N. Lawrence Edwards is Professor of Medicine, Division of Rheumatology and Clinical Immunology, as well as Program Director and Vice Chairman of the Department of Medicine at the University of Florida in Gainesville. Dr. Edwards obtained his undergraduate training at the University of Notre Dame and his medical degree from the University of Miami School of Medicine. He completed his training in Rheumatology at the Rackham Arthritis Research Center and the Clinical Research Center, University of Michigan in Ann Arbor where he remained on the faculty as Director of Education and Training in the Division of Rheumatology. In 1983 he moved to the University of Florida where he is the former Chief of the Division of Rheumatology and Clinical Immunology and former Rheumatology Program Director for 15 years. For the past 19 years he has been Vice Chairman of the Department of Medicine and Program Director of the Medicine Residency Training Program at the University of Florida. Dr. Edwards is an active member of many professional organizations including the American College of Rheumatology, American College of Physicians, the Association of Program Directors in Internal Medicine and is Past-President of the National Society of Clinical Rheumatologists. He is on the Executive Board of the Florida Chapter of ACP, the Co-chair of the Gout Interest Group for OMERACT between 2005-2016 and the Chairman and CEO of the Gout Education Society since its founding in 2005. He has authored over one hundred and fifty scientific articles, book chapters and reviews on the topics of hyperuricemia, gout, and purine metabolism. He is a Master of both the American College of Physicians and the American College of Rheumatologists.

Returning guest, Dr. Jeremy Levin, Chairman and CEO of Ovid Therapeutics, Inc., and former chairman of the global Biotechnology Innovation Organization (BIO) discusses the new COVID variant Delta-Plus, a virus that mutated from the highly infective Delta version, and why vaccinations are so crucial. #OvidTherapeutics #DeltaPlus #COVID Dr. Jeremy M. Levin is Chairman and CEO of Ovid Therapeutics Inc (NASDAQ:OVID), a company whose mission is to bring treatment to patients with rare neurological conditions. Dr. Levin is a former chairman of the Biotechnology Innovation Organization (BIO). Prior to founding Ovid, Dr. Levin was president and CEO of Teva Pharmaceutical Industries Ltd., (TLV: TEVA). Dr. Levin was voted as one of the twenty-five most influential biotechnology leaders by Fierce Biotech and one of the top three biotechnology CEOs in 2020 by The Healthcare Technology Report.

Dr. Ryan Mathis, MD, Vice President of Commercial Strategy at PolarityTE discusses SkinTE™ an innovative alternative for the treatment of chronic wounds, like diabetic foot ulcers (DFUs). He talks about the science behind SkinTE™, how it's made of a patient's own full-thickness skin, which retains the endogenous regenerative cellular populations found throughout his/her skin within multicellular segments. He also shares information from real-world studies of difficult to treat wounds. SkinTE™ is on track for IND submission in the second half of 2021. #woundcareskin #regenerativemedicine #tissueengineering Ryan K. Mathis, MD. Ryan earned his undergraduate and medical degrees at Penn State University before joining the Medstar Georgetown University Plastic Surgery Department as a resident. While at Georgetown, Ryan took leadership roles on the House Staff Quality Council and the Graduate Medical Education Council; he also received numerous awards from his peers and colleagues for distinguished clinical performance and for medical education. Ryan has published multiple papers and presented on various clinical and basic science research topics in the fields of plastic surgery, cardiac surgery, and wound care. Ryan left residency in 2017 to join PolarityTE and help translate the technology. Since joining Ryan has led multiple departments in the organization including Clinical Operations, Medical Affairs, Marketing, Market Access, Business development and Commercial. Ryan also serves as an advisor for numerous early-stage biotechnology and diagnostic companies and a visiting Professor for the Biotechnology Program at Georgetown University.

Returning guest, Dr. Bruce Sands, M.D., M.S., Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at Mount Sinai Hospital and the Dr. Burrill B. Crohn Professor of Medicine (Gastroenterology), at the Icahn Institute for Medicine at Mount Sinai discusses new data presented at the 16th Congress of European Crohn's and Colitis Organisation (ECCO) from a trial evaluating biologic induction and maintenance therapy for moderately to severely active ulcerative colitis. #ECCO2021 #UlcerativeColitis Bruce E. Sands, M.D., M.S., Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at Mount Sinai Hospital and the Dr. Burrill B. Crohn Professor of Medicine (Gastroenterology), at the Icahn Institute for Medicine at Mount Sinai is the study spokesperson for the three-year data from the long-term extension (LTE) of UNIFI, a Phase 3 protocol designed to evaluate the safety and efficacy of STELARA induction and maintenance dosing for the treatment of moderately to severely active ulcerative colitis in adults who demonstrated an inadequate response to or were unable to tolerate conventional (e.g., corticosteroids, immunomodulators) or biologic (e.g., one or more TNF blockers or vedolizumab) therapies. Dr. Sands' clinical research includes treating inflammatory bowel disease and clinical investigations of new therapeutics. He serves as a reviewer for the New England Journal of Medicine and is a fellow of the American College of Gastroenterology and the American Gastroenterological Association.

Leon Lerman, CEO of Cynerio, the leading provider of Healthcare IoT cybersecurity and asset management solutions discusses the biggest security challenges for healthcare in a post-COVID environment, why health systems should move to the Zero Trust model to secure their systems and devices, and whether governing bodies should provide cybersecurity requirements for healthcare. #Cynerio #HealthcareIoT Leon Lerman is the co-founder and CEO of Cynerio, Inc., a full-suite Healthcare IoT platform that enables healthcare providers to secure patient data and connected devices against cyber threats. He has over 15 years of experience in innovative technology development, served in Israel's elite Unit 8200 cyber technology division, has served as a trusted security advisor to Fortune 500 companies, and has earned international recognition for excellence in the cybersecurity industry.

Returning guest, Dr. Gregg Sylvester, Chief Medical Officer at Seqirus, a global leader in influenza prevention, discusses data from a first-of-its-kind co-administration study conducted by Novavax of the SARS-CoV-2 vaccine candidate (Novavax, NVX-CoV2373) and an approved influenza vaccine (Seqirus, Flucelvax Quadrivalent and Fluad). He talks about the potential advantages for patients and physicians to co-administer an approved COVID-19 and influenza vaccine, how these findings may impact proposed immunization scheduling for varying age groups and alter CDC recommendations, and the importance of these findings as we approach a critical 2021/22 influenza season while many populations are still in need of a primary COVID-19 vaccine series or booster dose. #COVID #Influenza #Seqirus Dr. Gregg Sylvester serves as the Chief Medical Officer of Seqirus. He has been with the company since 2016, previously serving as Vice President of Medical Affairs. Prior to this, Dr. Sylvester held a variety of senior management positions, including Global Medical Lead for Pfizer's pediatric pneumococcal vaccine and Worldwide Medical Lead for Merck's HPV vaccine and Cabinet Secretary for Delaware's Health & Social Services. Dr. Sylvester is a preventive medicine expert with a passion for disease prevention and health promotion on a local, statewide, and global basis. He has focused his career on developing sound health policy, implementing innovative public health programs and accelerating vaccine use worldwide.

Mike Lipps, CEO of Intelerad, a global leader in medical image management discusses why hospitals and health systems need fewer integrations to be able to truly manage their data and images and how a greater focus on data analytics can improve collaborative care. He also talks about the company's recent growth and momentum that furthers the company's mission to provide customers with the most comprehensive enterprise imaging platform in the industry. #Interlad #Interoperability With over 20 years of software industry experience at companies such as Intuit and LexisNexis, Mike Lipps, CEO of Intelerad, has a proven track record of driving transformative growth. In his current role, Mike is focused on expanding Intelerad's market penetration and coverage in the United States. Previously, as CEO of global enterprise software provider insightsoftware, Mike led the company through 14 acquisitions and over 400% growth in two years.

Dr. Rajesh Rajpal, MD, Global Head of Clinical and Medical Affairs, Johnson & Johnson Vision discusses the launch and availability of their TECNIS Synergy™ in the United States and Canada. This next-generation presbyopia-correcting intraocular (PC-IOL) lens offers cataract patients the widest range of continuous vision, and best near vision among leading PC-IOLs, without the visual gaps seen with some multifocal technology. He talks about how this new next-gen lens was developed​,​ designed​,​ and the science behind it​, as well as other innovations in eye care solutions.​ #TECNISSynergy #Cataracts Rajesh Rajpal, M.D. is Chief Medical Officer and Global Head of Clinical and Medical Affairs for Johnson & Johnson Vision. In this role, Dr. Rajpal leads the integration of rapidly evolving medical and clinical insights into new product development to address unmet needs of patients and eye care professionals around the world. He also oversees clinical trials and the generation of surgical and vision care evidence and serves as the critical liaison to government agencies and to the academic, scientific, and industry communities. Dr. Rajpal joined Johnson & Johnson Vision in 2020 from Avedro (acquired by Glaukos), where he served as Chief Medical Officer. He was a member of the senior executive team that led to an IPO and subsequent acquisition and directly oversaw clinical operations, medical affairs, regulatory affairs, and professional relations for professional societies and clinicians. Active in research and professional education, Dr. Rajpal has served as principal investigator in numerous clinical trials, authored multiple original peer-reviewed publications and textbook chapters, and has lectured internationally on topics related to corneal disease, cataract and refractive surgery. In addition to others, he is a recipient of the Senior Achievement and Secretariat awards from the American Academy of Ophthalmology. He currently holds appointments on the clinical faculties of Georgetown University Medical Center and Virginia Commonwealth University and serves as the Cornea Consultant to the Walter Reed National Military Medical Center. He is certified by and is a Diplomate of the American Board of Ophthalmology. He is a member of the American Academy of Ophthalmology, the American Society of Cataract and Refractive Surgery, Cedars/Aspens, AECOS, and the International Society of Refractive Surgery. Additionally, he has served as President and on the Board of Directors of the Washington D.C. Ophthalmology Society. He is the founder of the See Clearly Vision Group, an ophthalmology and optometry group practice with multiple offices in the metropolitan Washington, DC area. Dr. Rajpal has been regularly recognized as a Top Doctor by Washingtonian Magazine, Northern Virginia Magazine, and Consumers' Research Council of America. He was the first eye surgeon in Washington, D.C. to perform Laser Vision Correction as part of the clinical trials for FDA approval.

Dr. Clive Ward-Able is the Medical & Scientific Affairs Consultant of NeonMind Biosciences, a company exploring psilocybin as an alternative approach to weight loss and appetite suppression. He shares his insights on the potential of psychedelics in the treatment of obesity, the current trials underway, and what the future may hold. #NeonmindBiosciences #WeightLoss Dr. Clive Ward-Able is a physician and a pharmacist who has worked in the pharmaceutical industry for over 28 years with 21 of those at the executive level. He has worked in large and small pharmaceutical and biotechnology companies in Canada, the U.S., UK, Switzerland, and South Africa in the departments of R&D, medical, marketing, and sales. He is currently a member of the Board of Directors for Clinical Trials Ontario and has been a member of the Medical & Scientific Advisory Committee of Innovative Medicines Canada.

Dr. Karan Desai, MD, hand and upper extremity surgeon at Orlando Health Jewett Orthopedic Institute discusses how care for serious injuries at a level 1 trauma center can make the difference between amputation and recovery. He recently saved the arm of a paramedic that was bitten by an alligator. #Injuries Karan Desai, MD, is a board-eligible hand surgeon with Orlando Health Jewett Orthopedic Institute, where he specializes in both operative and non-operative treatment of the hand and upper extremity. In addition to managing all aspects of traumatic and elective hand and upper extremity surgery, Dr. Desai also has extensive training in microsurgery and is skilled in complex reconstruction of the brachial plexus, peripheral nerves, bones, joints, and soft tissues, using methods such as free tissue transfers and nerve transfers. He earned his medical degree from the University of South Florida, School of Medicine in Tampa, where he graduated with Alpha Omega Alpha distinction and earned an undergraduate degree cum laude from the University of Florida in Gainesville. Dr. Desai completed an internship and residency in general surgery and another residency in plastic and reconstructive surgery at Emory University and Grady Hospital in Atlanta, GA. This was followed by a combined orthopedic and plastic hand and upper extremity surgery fellowship at New York University, Langone School of Medicine in New York. Dr. Desai is active as a candidate member in many professional organizations, including American Society for Surgery of the Hand (ASSH) and American Association for Hand Surgery (AAHS). He has authored numerous book chapters and journal articles and presented his research at national and regional conferences, some of which have resulted in first place awards. He is fluent in English, Hindi and Gujarati.

Dr. Juan Camilo Arjona Ferreira, Chief Medical Officer of Myovant Sciences discusses uterine fibroids and the recent FDA approval of MYFEMBREE® for the treatment of heavy menstrual bleeding associated with uterine fibroids. MYFEMBREE is also being studied in endometriosis. #MyovantSciences #MYFEMBREE Juan Camilo Arjona Ferreira, MD, Chief Medical Officer of Myovant Sciences. Dr. Arjona Ferreira was previously Senior Vice President, Clinical Development at Shionogi. At Shionogi, Dr. Arjona Ferreira was responsible for leading the company's U.S. Clinical Development organization and he served on the company's U.S. Senior Leadership Team and the Global Scientific Committee. Prior to joining Shionogi, Dr. Arjona Ferreira spent over a decade at Merck & Co. where he was Executive Director of Clinical Research in Women's Health. At Merck, he chaired the product development teams for all programs in contraception and women's health. Dr. Arjona Ferreira earned his MD and completed his postgraduate specialist training in Obstetrics and Gynecology at Colegio Mayor del Rosario in Bogota, Colombia.

Returning guest, Dr. Lucie Ide, MD, PhD, founder and CEO of Rimidi discusses why multiple point solutions in healthIT are only a temporary fix, how providers can integrate such solutions to achieve better health outcomes across their entire population of patients, and how combining remote patient monitoring (RPM), chronic care management (CCM), telehealth and patient reported outcomes (PROs) with clinical decision support solutions will further enable holistic care, and drive greater efficiency for staff. #Rimidi #ValueBasedCare Lucienne Marie Ide, M.D., PH.D., is the founder and CEO of Rimidi, a cloud- based software platform that enables personalized management of health conditions across populations. She brings her diverse experiences in medicine, science, venture capital and technology to bear in leading Rimidi's strategy and vision. Motivated by the belief that we can do so much better as individuals, in industry and society, Lucie left clinical medicine to join the ranks of healthcare entrepreneurs who are trying to revolutionize an industry.

As much of the world's focus this past year has been on making progress in fighting off the COVID-19 pandemic, some remained focused on other raging epidemics that existed prior to the emergence of COVID-19 and continue to worsen over time. For Rohan Palekar, CEO of 89bio, a clinical-stage biopharmaceutical start-up, the raging epidemic is non-alcoholic steatohepatitis (NASH) and he discusses how they haven't allowed the pandemic or the failures of other NASH treatments to hinder their progress of developing a solution for NASH. He talks about what's on the horizon for 89bio, including plans for continuing the development of their lead candidate, BIO89-100 with the initiation of a Phase 2b trial for the treatment of (NASH). #89bio #NASH Rohan Palekar is a seasoned C-suite executive with over 25 years of experience in the biopharmaceutical industry. Most recently, Rohan was the president and CEO of Avanir Pharmaceuticals (2015-2017) after serving as its EVP-Chief Operations Officer (2015). Rohan joined Avanir in 2012 as SVP-Chief Commercial Officer (CCO) and as part of the senior leadership team led the organization through a dynamic growth phase. Avanir was acquired by Otsuka Pharmaceuticals in 2015. Prior to Avanir, Rohan served as the CCO of Medivation (2008-2011), where he oversaw commercial, medical affairs, CMC & manufacturing, and public relations. Earlier in his career, Rohan spent 16 years at Johnson & Johnson in various senior commercial and strategic management roles, including worldwide VP of immunology and VP of sales and marketing at Centocor. Rohan holds an MBA from the Amos Tuck School of Business Administration at Dartmouth College and a BA/BS in law and accounting from the University of Bombay.

Lead author, Dr. Philip Mease, MD, Director of Rheumatology Research at the Swedish Medical Center/Providence St. Joseph Health and Clinical Professor at the University of Washington School of Medicine, discusses new data from the Phase 3 DISCOVER-1 and DISCOVER-2 studies published in "The Lancet Rheumatology" (July 2021) on the efficacy of guselkumab on axial symptoms in patients with active psoriatic arthritis. Up to 70% of PsA patients experience axial symptoms. #TREMFYA #PsoriaticArthritis Philip J Mease, MD, is a Clinical Professor at the University of Washington School of Medicine and Director of Rheumatology Research at the Swedish Medical Center in Seattle, WA. Dr Mease's clinical practice is based at Seattle Rheumatology Associates. He received his undergraduate and medical degrees at Stanford University Medical School, and he completed his residency in internal medicine at the University of Washington's School of Medicine, where he also served as chief resident and fellow in rheumatology. Dr Mease conducts clinical trials on emerging therapies for rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, osteoarthritis, and lupus. He also conducts research in disease state metrics and is the co-chair of three working groups for OMERACT (Outcome Measures in Rheumatology Clinical Trials) on psoriatic arthritis, fibromyalgia, and single-joint assessment, as well as a member of the Soluble Biomarker working group. Dr Mease is a founding organizer and President of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), a member of SPARTAN (Spondyloarthritis Research & Treatment Network), and a member of TREG (The Rheumatology Education Group). He has published 18 book chapters and nearly 400 journal articles.

Dr. Jennifer Gudeman, Vice President, Medical and Clinical Affairs at Avadel Pharmaceuticals discusses new clinical data from the pivotal phase 3 REST-ON clinical trial that was presented at the SLEEP 2021 Annual Meeting. The investigational therapy, FT218, for the treatment of excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy is currently under review at the FDA with a PDUFA target date of October 15, 2021. She also talks about the current treatment landscape and the unmet need among patients for a differentiated treatment option. #AvadelPharmaceuticals #SLEEP2021 Dr. Jennifer Gudeman was appointed Vice President, Medical and Clinical Affairs in December 2020. In 2017, Dr. Gudeman received the Healthcare Businesswomen's “Rising Star” award. During her career, she has led or contributed to six commercial product launches and three clinical development programs, as well as led interactions with medical societies and patient advocacy organizations to help ensure that commercial medications fulfill their clinically proven therapeutic benefits to patients and providers. Dr Gudeman has published numerous peer-reviewed papers and provided domestic and international presentations on partnership with industry for drug development in high-risk pregnancies. Prior to joining Avadel, Dr. Gudeman was Vice President, Medical Affairs at AMAG Pharmaceuticals, overseeing a team of medical science liaisons and scientific communications. Prior to her time at AMAG Pharmaceuticals, she was Director of Medical Affairs at Lumara Health. Additionally, she began her industry career at Mallinckrodt Pharmaceuticals. Dr. Gudeman graduated summa cum laude with a bachelor's degree in pharmacy and magna cum laude with a doctorate in pharmacy from St. Louis College of Pharmacy in 1999 and 2000, respectively.

Dr. Jeffrey Cleland, Ph.D., Chairman, CEO and President of Ashvattha Therapeutics, a clinical stage biotech company discusses treatments that are in development to address inflammation of the brain caused by COVID. They recently announced positive interim results on its ongoing phase 2 PRANA clinical study, which showed that OP-101, a novel hydroxyl dendrimer therapeutic, has the ability to successfully cross the blood brain barrier and suppress hyperinflammation. The company is also developing a class of novel hydroxyl dendrimer therapeutics that they hope will become the future of targeted therapies and unlock new levels of patient care across oncology, ophthalmology, and inflammatory diseases. #AshvatthaTherapeutics Dr. Cleland has 30 years of industry experience in research and development, including more than a decade at Genentech, Inc. His experience in startups includes major roles in obtaining more than $450 million in capital at stages from Series A through D and exit via IPO including over $300 million in capital raised as CEO. As the founding CEO of Versartis (VSAR), he led one of top biotech IPOs of all time. After Versartis, he led the Series B financing and clinical translation of novel Johns Hopkins University technology as CEO of Graybug Vision (GRAY). He held executive management positions at BaroFold, Novacea and Targesome, and has managed directly all aspects of drug development and late-stage research. While at Genentech, Dr. Cleland served in product development and manufacturing roles. He held important leadership roles in the successful approval of two drugs, Herceptin® and Nutropin Depot®, as well as in early work on Lucentis®, Avastin®, and Kadcyla®. He holds a BS in Chemical Engineering from the University of California, Davis and a PhD in Chemical Engineering from the Massachusetts Institute of Technology. Dr. Cleland has authored more than 100 articles and four books, and holds several issued patents. He serves on the Boards of BIO, Exicure, and Zylem and has advisory roles with small emerging biotechnology companies.

Adam Levy, CEO of NEXGEL, advanced hydrogel solutions, discusses their unique water-based hydrogels designed differently from all other adhesives, tapes and surgical drapes that allow patients' skin to remain hydrated, without rashes, and do not hurt patients when they are removed. #NEXGEL Adam Levy, CEO of NEXGEL has 34 years of expertise in capital markets, consumer products, marketing, television/radio advertising and direct to consumer sales. Previously, he led the successful turn-around of several financially distressed music companies as CEO of Warlock Record.

Millions of people worldwide are currently impacted by heart valve disease, and one in eight people aged 75 and older have the most common form, aortic stenosis (AS). Currently, treatment options for AS include transcatheter aortic valve replacement (TAVR), a minimally invasive procedure, or a surgical aortic valve replacement (SAVR), also known as open heart surgery. Dr. Purvi Parwani, M.D., Director of the Women's Cardiovascular Health Clinic at Loma Linda International Heart Institute discusses new findings from a CardioSurve survey, sponsored by Medtronic and conducted by the American College of Cardiology, that reveals more than half of cardiologists believe patient preparation may lead to better quality discussions around treatment options for heart valve disease. However, the survey also uncovered cardiologists feel that their symptomatic severe AS patients are not as informed as they should be about their treatment options. Dr. Parwani will address why shared decision making is critical to individualized care and how to advance patient/physician dialogue. #CardioSurve Purvi Parwani, M.D. currently serves as the director of the Women's Cardiovascular Health Clinic at Loma Linda International Heart Institute. Dr. Parwani recently sat as a panelist the American College of Cardiology Virtual Symposium and discussed outcomes of the ACC CardioSurve panelist survey. Dr. Parwani graduated from the B.J. Medical College in Ahmedabad and is board certified by the American Board of Internal Medicine, Cardiovascular Disease and American Board of Internal Medicine, Internal Medicine.

Dr. Reid Robison, Chief Medical Officer of Novamind discusses psychedelic medicine and Novamind's leading network of psychedelic-assisted psychiatry clinics in America. Novamind is in a rapid expansion phase as they seek to build their growing network of clinics, research sites and therapeutic retreats specialized in psychedelic medicine. #Novamind #PsychadelicMedicine Dr. Reid Robison is a board-certified psychiatrist who was named Best Psychiatrist in Utah by Salt Lake City Weekly's Best of Utah Body & Mind 2020. Dr. Robison is the co-founder of Cedar Psychiatry and serves as the Medical Director for the Center for Change, a leading Eating Disorder center. He is currently the coordinating investigator for the MAPS-sponsored MDMA-assisted psychotherapy study of eating disorders. As an early adopter and researcher of ketamine in psychiatry, Dr. Robison led a pivotal IV ketamine study for treatment-resistant depression by Janssen, leading up to the company's recent FDA-approval of Spravato™. To date, Dr. Robison has guided thousands of ketamine therapy journeys and hundreds of Spravato™ dosing sessions. As a social entrepreneur, Dr. Robison has built a number of purpose-driven companies including Tute Genomics which was acquired by PierianDx in 2016. Dr. Robison is also an adjunct professor at both the University of Utah and Brigham Young University and is the founder of the Polizzi Free Clinic, a free mental health clinic for marginalized people based in Salt Lake City, Utah.

Dr. Anthony Rullo, PhD, Assistant Professor of Medicine at McMaster University discusses the Anna Biosciences Syntem Platform that deploys engineered proprietary molecules to create synthetic immunity. Research suggests the platform can inhibit viral infection and aid in the removal of COVID-19 infected cells. In partnership with McMaster University, Anna Biosciences has proven its initial successes in the laboratory and is now accelerating its commercialization effort to bring this potential COVID-19 treatment to market. The platform also shows strong promise for use against cancer and other pathogens. #AnnaBiosciences #Syntem #COVID19 Anthony Rullo, Ph.D, is an Assistant Professor of Medicine at McMaster University where he has pioneered small molecule “proximity-inducing” therapeutic strategies with applications in immuno-oncology and anti-viral immunotherapeutics. In 2017 he founded the Rullo Laboratory, a translational chemical biology lab integrated within the department of medicine and the McMaster Immunology Research Center (MIRC). Dr. Rullo's scientific training encompasses several aspects of organic synthesis, carbohydrate chemistry, physical biochemistry, and immunology. He received his Ph.D. in Organic and Biochemistry from the University of Toronto under the supervision of Prof. Mark Nitz, where he developed fluorescent chemical probes of complex glycosaminoglycan binding interactions, in addition to new bio-orthogonal affinity labelling strategies. This was followed by postdoctoral training under the mentorship of Prof. David A. Spiegel at Yale where Dr Rullo pioneered the development of synthetic antibody engagement molecules targeting uPAR expressing cancers. With his leading role in the development of the Syntem Platform, Dr. Rullo serves as the scientific co-founder of Anna Biosciences. As part of the development of the Syntem Platform, Dr. Rullo has engaged supporting experts in medicinal chemistry and immunology/virology.

Dr. Brian LaMoreaux, MD, MS, Medical Director, Medical Affairs at Horizon Therapeutics plc discusses data presented at the 2021 European Alliance Of Associations For Rheumatology (EULAR) from the MIRROR open-label trial which looked at KRYSTEXXA® in combination with immunomodulator methotrexate in uncontrolled gout. EULAR abstract [AB0630]. Dr. Brian LaMoreaux is an internist and rheumatologist who joined Horizon Therapeutics in July 2016. He blends science and compassion in his approach to change outcomes for patients living with gout, recognizing that to change the understanding of gout, new research and continued education is required.Brian collaborates with the scientific community to push forward emerging data and to generate a foundation for new clinical studies so that clinicians may better address gout and ultimately improve outcomes for patients. Brian prioritizes having a personal impact on his community and provides one-on-one care as a volunteer clinician a free clinic in downtown Chicago. #HorizonTherapeutics #KRYSTEXXA #UncontrolledGout

The safe adoption of AI can benefit mammography departments as they strive to deliver on the goals of the national breast screening program. Dr. Christopher Austin, Chief Medical Officer at Kheiron Medical Technologies, discusses the challenges that face Australia's breast screening programs and how AI can help address those challenges, learnings from the UK's National Health System's adoption of AI in breast screening, and how those learnings can benefit Australian radiologists and women. Dr. Christopher Austin serves as chief medical officer at Kheiron Medical Technologies where he contributes his extensive knowledge and expertise as a trained radiologist, epidemiologist, strategist and innovator with more than 20 years of combined clinical and industry expertise on a global level. He is a recognized thought leader in artificial intelligence and radiology, having worked with leading academic organizations to develop deep learning algorithms. Prior to joining Kheiron, Dr. Austin held healthcare management roles at GE Healthcare, serving as medical director of imaging AI and analytics, and as global radiology solutions director, where he was responsible for developing innovative solutions and AI strategy for diagnostic imaging. Previously, he held clinical and executive roles at a wide range of healthcare organizations including the University College London Hospital NHS Trust Foundation, NHS of Greater Glasgow and Clyde, and Doctor Career Choices. He earned his medical degree at The University of Glasgow and underwent his radiology training at the University College Hospital of London. He also holds a Master of Science degree in epidemiology at the University of London, and studied biomedical and clinical informatics at Oregon Health Sciences University. #ArtificialIntelligence #Radiology #Kheiron

Branko Kolvek, SVP of Operations at Pager, discusses the company's virtual care collaboration platform while exploring the differences between telehealth and virtual care. He'll also provide insight into how digital platforms can control healthcare costs, limit telehealth overutilization, and improve the patient experience. Offered through health plans, Pager's platform provides access to a care coordination team and combines omni-channel communications, artificial intelligence, and machine learning to deliver high-touch concierge services that guide patients along the entire care path, from chat and triage, to scheduling, customer service, e-prescribing, and follow-up care. Branko Kolvek is Senior Vice President of Operations at Pager, a virtual care collaboration platform that offers whole-person healthcare and hi-tech, hi-touch concierge services to connect patients with the care and services they need. In his current role, Mr. Kolvek oversees operational processes and care services to drive performance and create an improved patient experience through Pager's platform. Prior to his time at Pager, Mr. Kolvek served as the Vice President of Operations at Remedy Partners (now Signify Health: NYSE SGFY) where he implemented value-based initiatives with providers. As a Senior Associate at Alvarez & Marsal Healthcare Industry Group Mr. Kolvek executed financial and operational turnaround strategies with provider organization. With nearly 15 years of experience in the healthcare industry, Mr. Kolvek has worked with a number of different companies and startups to help them navigate the healthcare ecosystem. Mr. Kolvek is a graduate of Brown University where he earned a Sc.B. in Biology, and a graduate of Johns Hopkins Bloomberg School of Public Health, where he received his MHS in Health Finance and Management. #Pager #VirtualCare #Telehealth

Nancy Di Dia, Executive Director, Chief Diversity & Inclusion Officer & Head, US DICE at Boehringer Ingelheim USA discusses her 15 years as a D&I officer, her personal history, and how she nurtured the development of the D&I programs at a pharmaceutical industry giant. She shares her learnings on how to build sustainable change over time. Nancy Di Dia is Executive Director, Chief Diversity & Inclusion Officer & Head, US DICE at Boehringer Ingelheim USA. She brings more than 25 years of change and social experience in overall management, leadership and cultural change in the corporate world. Her experience has spanned financial services and healthcare. At Boehringer Ingelheim Nancy has responsibility for leading a culture of diversity, inclusion, engagement and belonging within BI's Animal Health, Biopharma and Human Pharma business units. In addition, Nancy is an (ICF) International credentialed and certified PCC Executive Coach with a focus on finding impactful ways to engage the brain in sustainable insights and change. She is an active member of the task force for Talent Innovation- a think tank and research group of leading global companies that leverages talent across the divides of gender, generation, geography and culture. Nancy is also on the board of the International Multicultural Institute (IMCI) a non-profit that offers service, knowledge and skills for individual and institutional change through inclusion. She was recently appointed to the Governor's council on Girls and Women in STEAM for the state of Connecticut and continues to act on the PhRMA chief diversity officer council to improve diversity in clinical studies. Nancy is fluent in Italian, an avid exerciser, rower and enjoys gardening, cooking and seeking out fine wines from around the world. #Diversity #Inclusion #SustainableChange

Co-founder Lawrence Kosick discusses GetSetUp, a company founded in 2019 to provide an online learning platform for older adults with classes taught by older adults. In recent months, GetSetUp has announced partnerships with various state government agencies to address issues associated with the pandemic, including a partnership with The New York State Office for the Aging (NYSOFA). Older adults in New York now have access to GetSetUp's 50,000 classes, featuring more than 300 different course options developed by and for older adults. The GetSetUp curriculum and community are designed to combat social isolation and promote independence through live, interactive classes and online connectivity with a community of more than 650,000 older adult learners from more than 160 countries around the globe. Neil Dsouza and Lawrence Kosick were trail running partners and seasoned technology executives who co-founded GetSetUp, a live, interactive learning platform for older adults who want to learn new skills, connect with others, and unlock new life experiences. Classes are taught by older adults and kept small to ensure everyone can actively participate. The platform helps older adults stay mentally and physically fit, creates economic opportunities through jobs and reskilling, and provides a community where people find meaning and purpose by helping each other and forming new connections. GetSetUp currently supports more than 650,000 older adults from 163 countries. Dsouza was the CEO of a Mumbai-based social enterprise, Zaya Learning Labs, that strived to provide world-class education for underprivileged children around the world. Kosick is a serial entrepreneur in the consumer and internet software space. #GetSetUp #Pandemic

Over the past year, many people have missed or postponed medical appointments due to the pandemic. For people with chronic conditions like multiple sclerosis (MS), a missed treatment or delayed care could lead to disease progression and debilitating relapses. Dr. Mitzi Joi Williams, MD, MS expert and board-certified neurologist discusses implications surrounding missed doctor's appointments, including irreversible disease progression, the importance of continuing treatment, and of identifying disease progression early. She urges people living with MS to continue seeking care or catch up on missed or postponed doctor visits due to the pandemic. Dr. Mitzi Joi Williams is a Board-Certified neurologist and Fellowship trained Multiple Sclerosis Specialist. Dr. Mitzi is passionate about educating and empowering people affected by MS to understand the disease process and the goals of treatment. She is a sought-after consultant, speaker, researcher and author. She has expertise in understanding MS in underserved and ethnic minority populations. She collaborates with national and international committees to advocate for people living with MS and encourage partnerships between patients and with their healthcare teams to improve shared decision making to combat this disease. She also is dedicated to raising awareness about the importance of research participation and encouraging diversity in clinical research. #MS #MultipleSclerosis

Dr. Sammy Elmariah, Director, Interventional Cardiology Research at Massachusetts General Hospital discusses his recent research "Transfemoral Tricuspid Valve Replacement In Patients With Tricuspid Regurgitation: 30-day Results Of The Triscend Study" which was recently presented at the 2021 American College of Cardiology's annual scientific meeting. Dr. Sammy Elmariah graduated from the University of Pennsylvania School of Medicine and completed his internal medicine residency training at the Hospital of the University of Pennsylvania. He subsequently served as Chief Medical Resident at Lankenau Hospital. Dr. Elmariah completed his fellowship in cardiovascular medicine at the Mount Sinai Hospital in New York where he also served as Chief Fellow. While a fellow, he also completed a Masters in Public Health at the Harvard School of Public Health. Dr. Elmariah completed further fellowship training in interventional cardiology and structural heart disease at the Massachusetts General Hospital. Currently, Dr. Elmariah is an interventional cardiologist and structural heart disease specialist at the Massachusetts General Hospital and Assistant Professor of Medicine at the Harvard Medical School. In addition, he serves as the Director of Interventional Structural Heart Disease at the Boston VA Healthcare System. He is also the Associate Director of Trial Design at the Harvard Clinical Research Institute.His clinical interest is in the management of valvular heart disease, coronary artery disease, and adult congenital heart disease. He performs transcatheter valve replacement, percutaneous coronary interventions (stents), and transcatheter closure of patent foramen ovale (PFO) and atrial septal defects (ASD).Dr. Elmariah has a specific research interest in valvular heart disease. In addition to ongoing clinical investigation of valve calcification and the progression of aortic stenosis, Dr. Elmariah is evaluating the impact of transcatheter aortic valve replacement on myocardial metabolism and myocardial remodeling. Dr. Elmariah is an MGH Heart Center Hassenfeld Research Scholar and has been awarded the Jeremiah Stamler Distinguished Young Investigator Award and an American College of Cardiology Young Investigator Award. #ACC21

Dr. Ellie Stang, a board-certified pediatrician and founder and CEO of ProgenyHealth, a healthcare company that applies evidence-based care management solutions to improve outcomes for premature and medically complex newborns, discusses how American women die in childbirth at a higher rate than in any other developed country, social determinants of health (SDOH), and how payers can effectively manage high-cost scenarios that require specialized expertise. #ProgenyHealth #PrematureNewborns #MedicallyComplexNewborns As the Founder and CEO of ProgenyHealth, she is responsible for the strategic direction of the company. This entails being ultimately responsible for day-to-day management decisions and for implementing the Company's long and short term plans. Prior to founding ProgenyHealth, Dr. Stang was a Regional Medical Director at a large managed Medicaid plan responsible for overseeing the medical management of their pediatric membership. Before entering managed care, she enjoyed many years in private practice as one of the founding partners of Bucks County Pediatrics, a practice of the University of Pennsylvania Health System. While in private practice, she was Co-Director of the newborn nursery at the Bucks County Campus of the Medical College of Pennsylvania. Dr. Stang received her medical degree from the Pennsylvania State University College of Medicine and completed her residency at Saint Christopher's Hospital for Children in Philadelphia. She is board certified in Pediatrics and a fellow of the American Academy of Pediatrics.

Today, up to 60% of elderly persons develop delirium during hospitalization for an injury or unintentional fall. Dr. Franco Garcia, geriatric medicine specialist at Massachusetts General Hospital discusses data presented during the 2021 American Geriatrics Society's Annual Meeting, that shows nutrition may be a modifiable risk factor for hospitalized, elderly orthopedic trauma patients. He shares key findings from his study, "Nutritional status is associated with new-onset delirium in elderly, acute care, orthopedic trauma patients: A single-center observational study". #AGS2021 Dr. Esteban Franco Garcia is a Geriatric Medicine Specialist in Boston, Massachusetts. He graduated with honors in 2003. Having more than 18 years of diverse experiences, especially in Geriatic Medicine, Internal Medicine, Dr. Esteban Franco Garcia affiliates with Massachusetts General Hospital, cooperates with many other doctors and specialists in medical group Massachusetts General Physicians Organization Inc.

Dr. Michael McCullar, CEO, and Dr. Hong Tang, Chief Medical Officer at OnQuality Pharmaceuticals, a clinical stage pharma company pioneering the discovery and development of targeted cancer supportive care therapies that address cancer treatment-related toxicities at the molecular level, discuss the company's lead pipeline candidate, OQL011, the first targeted treatment for the severe cancer med side effect Hand Foot Skin Reaction (HFSR). OQL011 is currently in Phase 2 study at onco-dermatology clinics across the country. It is a topical ointment that can be applied to the hands and feet, acting locally to restore VEGFR signaling while avoiding any interference with the main cancer med mechanism of action. Michael McCullar is the Chief Executive Officer of OnQuality Pharmaceuticals. He has more than 20 years of pharmaceutical experience in strategic planning and development, drug discovery and operation, business development and commercial operation. Previously he served as Chief Operating Officer at Tolero Pharmaceuticals, where he oversaw drug discovery and development activities as well as corporate development, and commercial planning. He played a major role in the acquisition of Tolero by Sumitomo Dainippon Pharma for $780M ($200M upfront). Prior to joining Tolero Pharmaceuticals, he held multiple roles at Astex Pharmaceuticals including Senior Vice President of Business Development where he was involved in the acquisition of Astex Pharmaceuticals by Otsuka for $886M in cash. In addition, he served as Vice President of Development and Operations and led the FDA approval of Dacogen for the treatment of MDS, while at SuperGen, Inc. Dr. McCullar earned a PhD from the University of California and an MBA from the W.P. Carey School of Business, Arizona State University. Dr. Hong Tang, Chief Medical Officer, and co-founder of OnQuality Pharmaceuticals. Hong is a Board-certified physician with more than 15 years' experience in both drug development and medical affairs, and conducted all phases of clinical trials. She served as VP, Executive Medical Director, Medical Director, and Medical Officer in Dendreon, Juno, Astellas, BMS and NIH. #OnQualityPharmaceuticals #OQL011

Newly appointed Chief Medical Officer of HD Medical, Inc., Shaun Setty, MD, discusses their flagship product, HD Steth, an FDA cleared Intelligent Stethoscope with ECG and PCG in a single device. It allows providers to capture unsurpassed sound fidelity enhanced by visualization on the HD Steth Android or Apple iOS app. He also talks about HD Medical's new HealthyU device, an all-in-one remote patient monitor, to be launched in the US in January 2022. Dr. Setty is a cardiothoracic surgeon in Los Angeles, CA, with over 13 years of experience in pediatric and adult congenital cardiac surgery. Dr. Setty is triple-board certified in surgery, thoracic surgery and congenital heart surgery, with experience in all aspects of cardiac surgery. Dr. Setty began his medical education at the Medical College of Ohio, where he graduated with Alpha Omega Alpha honors, followed by a general surgery residency at Oregon Health & Science University. He went on to complete his cardiothoracic surgery training at the University of Minnesota/ Lillehei Heart Institute, the birthplace of modern cardiac surgery. Dr. Setty continued on to do his congenital cardiac surgery fellowship at the renowned Royal Children's Hospital in Melbourne, Australia and spent a year at Green Lane Hospital in New Zealand as a pediatric and adult cardiac surgery fellow. He also has experience in robotic and transplant surgery and is currently involved in multiple basic and clinical cardiac research projects. He has led over a dozen humanitarian mission trips performing cardiac surgery globally to help those who are without access to surgical cardiac care. #HDMedicalInc #HDSteth #IntelligentStethoscope

Returning guest, Dr. Andrew Chan, MD, MPH, Gastroenterologist, Chief, Clinical and Translational Epidemiology Unit, Director of Cancer Epidemiology, Massachusetts General Cancer Center discusses his recent research "Associations Between Screening Lower Endoscopy and Colorectal Cancer Incidence in Younger Adults", which was recently presented at the 2021 Digestive Disease Week annual scientific meeting. Andrew T. Chan, M.D., M.P.H. is a Professor of Medicine at Harvard Medical School (HMS), Chief of the Clinical and Translational Epidemiology Unit, and the Program Director for gastroenterology training at Massachusetts General Hospital (MGH). As a clinical gastroenterologist, Dr. Chan specializes in familial gastrointestinal cancer syndromes and cancer prevention. #DDW21 #LowerEndoscopy #ColorectalCancer